While total segment revenue declined 6.6% year-over-year due to weak truckload (TL) demand and lower rates, gross margins ...

Stifel's commentary also mentioned that C.H. Robinson has been considered a "show-me story," indicating that the market has been waiting for proof of the company's performance and strategy ...

Stifel upgraded C.H. Robinson (CHRW) to Buy from Hold with an unchanged price target of $113. The company reported “solid” Q4 results and the ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

The natural beauty of West Virginia will be celebrated both musically and visually in the Wheeling Symphony Orchestra’s upcoming performance, “Nature. Beauty.” Set for 2 p.m., Feb. 8, at the Capitol ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

In a report released today, Michael Brown from Wells Fargo maintained a Buy rating on Stifel Financial (SF – Research Report), with a price ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.

Shares of Stifel Financial were moving higher after it reported fourth-quarter adjusted earnings that beat Wall Street ...